Barclays
MLYS icon

Barclays’s Mineralys Therapeutics MLYS Stock Holding History

Barclays’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$918K Sell
33,877
-189,406
-85% -$5.55M ﹤0.01% 2810
2025
Q4 		$8.1M Sell
223,283
-430,547
-66% -$17.3M ﹤0.01% 1851
2025
Q3 		$24.8M Buy
653,830
+509,946
+354% +$11M 0.01% 1102
2025
Q2 		$1.95M Buy
143,884
+110,984
+337% +$1.61M ﹤0.01% 2870
2025
Q1 		$522K Sell
32,900
-13,496
-29% -$155K ﹤0.01% 3510
2024
Q4 		$571K Buy
46,396
+8,178
+21% +$107K ﹤0.01% 3746
2024
Q3 		$463K Buy
38,218
+28,208
+282% +$341K ﹤0.01% 3830
2024
Q2 		$117K Sell
10,010
-3,651
-27% -$46K ﹤0.01% 3833
2024
Q1 		$176K Sell
13,661
-13,113
-49% -$162K ﹤0.01% 4188
2023
Q4 		$230K Buy
26,774
+24,320
+991% +$191K ﹤0.01% 4356
2023
Q3 		$23.3K Sell
2,454
-324
-12% -$4.22K ﹤0.01% 4141
2023
Q2 		$47.4K Sell
2,778
-9,758
-78% -$146K ﹤0.01% 3860
2023
Q1 		$196K Buy
+12,536
New +$211K ﹤0.01% 3799

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Barclays's MLYS Position: Q1 2026 in Review

Barclays reduced its Mineralys Therapeutics (MLYS) stake by 85% in Q1 2026, selling an estimated $5.55M and leaving 33,877 shares worth $918K. The position accounts for ﹤0.01% of the portfolio, ranked #2810.

Barclays first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $24.8M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Barclays held 33,877 shares of Mineralys Therapeutics worth $918K as of Q1 2026.
  • Barclays sold 189,406 Mineralys Therapeutics shares in Q1 2026, an estimated $5.55M.
  • Mineralys Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2810 holding.
  • Barclays first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Barclays's Mineralys Therapeutics position peaked at $24.8M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.